Schick C, Pemberton P A, Shi G P, Kamachi Y, Cataltepe S, Bartuski A J, Gornstein E R, Brömme D, Chapman H A, Silverman G A
Department of Pediatrics, The Harvard Medical School, Children's Hospital, 300 Longwood Avenue, Boston, Massachusetts 02115, USA.
Biochemistry. 1998 Apr 14;37(15):5258-66. doi: 10.1021/bi972521d.
The human squamous cell carcinoma antigens (SCCA) 1 and 2 are tandemly arrayed genes that encode two high-molecular-weight serine proteinase inhibitors (serpins). Although these proteins are 92% identical, differences in their reactive site loops suggest that they inhibit different types of proteinases. Our previous studies show that SCCA2 inhibits chymotrypsin-like serine proteinases [Schick et al. (1997) J. Biol. Chem. 272, 1849-1855]. We now show that, unlike SCCA2, SCCA1 lacks inhibitory activity against any of the more common types of serine proteinases but is a potent cross-class inhibitor of the archetypal lysosomal cysteine proteinases cathepsins K, L, and S. Kinetic analysis revealed that SCCA1 interacted with cathepsins K, L, and S at 1:1 stoichiometry and with second-order rate constants >/= 1 x 10(5) M-1 s-1. These rate constants were comparable to those obtained with the prototypical physiological cysteine proteinase inhibitor, cystatin C. Also relative to cystatin C, SCCA1 was a more potent inhibitor of cathepsin K-mediated elastolytic activity by forming longer lived inhibitor-proteinase complexes. The t1/2 of SCCA1-cathepsin S complexes was >1155 min, whereas that of cystatin C-cathepsin complexes was 55 min. Cleavage between the Gly and Ser residues of the reactive site loop and detection of a stable SCCA1-cathepsin S complex by sodium dodecyl sulfate-polyacrylamide gel electrophoresis suggested that the serpin interacted with the cysteine proteinase in a manner similar to that observed for typical serpin-serine proteinase interactions. These data suggest that, contingent upon their reactive site loop sequences, mammalian serpins, in general, utilize their dynamic tertiary structure to trap proteinases from more than one mechanistic class and that SCCA1, in particular, may be involved in a novel inhibitory pathway aimed at regulating a powerful array of lysosomal cysteine proteinases.
人鳞状细胞癌抗原(SCCA)1和2是串联排列的基因,编码两种高分子量丝氨酸蛋白酶抑制剂(丝氨酸蛋白酶抑制剂)。尽管这些蛋白质有92%的同源性,但它们反应位点环的差异表明它们抑制不同类型的蛋白酶。我们之前的研究表明SCCA2抑制胰凝乳蛋白酶样丝氨酸蛋白酶[施克等人(1997年)《生物化学杂志》272卷,第1849 - 1855页]。我们现在表明,与SCCA2不同,SCCA1对任何一种更常见类型的丝氨酸蛋白酶都缺乏抑制活性,但却是原型溶酶体半胱氨酸蛋白酶组织蛋白酶K、L和S的有效跨类抑制剂。动力学分析表明,SCCA1与组织蛋白酶K、L和S以1:1的化学计量比相互作用,二级速率常数≥1×10⁵ M⁻¹ s⁻¹。这些速率常数与用原型生理性半胱氨酸蛋白酶抑制剂胱抑素C获得的速率常数相当。同样相对于胱抑素C,SCCA1通过形成寿命更长的抑制剂 - 蛋白酶复合物,是组织蛋白酶K介导的弹性蛋白酶活性的更有效抑制剂。SCCA1 - 组织蛋白酶S复合物的半衰期>1155分钟,而胱抑素C - 组织蛋白酶复合物的半衰期为55分钟。反应位点环的甘氨酸和丝氨酸残基之间的切割以及通过十二烷基硫酸钠 - 聚丙烯酰胺凝胶电泳检测到稳定的SCCA1 - 组织蛋白酶S复合物,表明丝氨酸蛋白酶抑制剂与半胱氨酸蛋白酶的相互作用方式类似于典型丝氨酸蛋白酶抑制剂与丝氨酸蛋白酶相互作用所观察到的方式。这些数据表明,取决于它们的反应位点环序列,一般来说,哺乳动物丝氨酸蛋白酶抑制剂利用其动态三级结构来捕获来自不止一个机制类别的蛋白酶,特别是SCCA1可能参与了一种旨在调节一系列强大的溶酶体半胱氨酸蛋白酶的新型抑制途径。